Powles, T., Rosenberg, J. E., Gupta, S., Loriot, Y., Grimm, M., Strauss, J., Gelb, A. B., McLean, S. E., Yang, L., Lobo, M., Callejo, D. P., Zhao, J. L., Cheng, J. D., Galsky, M. D. (2026). IZABRIGHT-Bladder01: A randomized, open-label, phase 2/3 trial of izalontamab brengitecan (iza-bren; BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), vs platinum-based chemotherapy (PBC) for patients (pts) with advanced urothelial cancer (aUC) and disease progression on or after immunotherapy.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.tps883